Trial Profile

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2026 According to a NMD Pharma media release, data from this study has been presented in a late-breaking oral presentation at the 2026 Peripheral Neuroscience Association (PNS) Annual Meeting held in Maastricht, The Netherlands from June 13-16, 2026.
17 Jun 2026 Results presented in a NMD Pharma Media Release.
10 Mar 2026 According to a NMD Pharma media release, data from this study were presented at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com